Document is current
Any future updates will be listed below
-
Authors
Abdallah, Khadidja https://orcid.org/0000-0003-0149-9213
Claes, Kathleen
Huys, Isabelle
Follon, Lennert
Calis, Charlotte
Simoens, Steven
-
Funding
Funding for this research was provided by:
Fonds Wetenschappelijk Onderzoek (G0B9819N)
- License Information
-
More Information
Article History
Received: 15 March 2022
Accepted: 20 November 2022
First Online: 9 December 2022
Declarations
:
: “The Research Ethics Committee UZ/KU Leuven hereby grants favorable advice to the proposed study, as it was described in the protocol. The Commission is of the opinion that from an ethical standpoint there are no objections to the proposed study. The study was approved on 09–09–2020.” Committee’s reference number: MP015702.
: Not applicable.
: Steven Simoens (SS) has previously conducted research about market access of orphan drugs sponsored by the Belgian Health Care Knowledge Centre and by Genzyme (now Sanofi), and he has participated in an orphan drug roundtable sponsored by Celgene. SS is a member of the ISPOR Rare Disease Special Interest Group’s Challenges in Research and Health Technology Assessment of Rare Disease Technologies Working Group, the International Working Group on Orphan Drugs, and the Innoval Working Group on Ultra-Rare Disorders. Kathleen Claes has received consultancy fees from Alexion, Astellas and Sanofi. Isabelle Huys reports no conflict of interest.
